Skip to content
2000
Volume 26, Issue 1
  • ISSN: 1871-5206
  • E-ISSN: 1875-5992

Abstract

Aromatase, a crucial enzyme assigned for transforming androgen into estrogen, has a vital function in the advancement of drug-resistant breast cancers that respond to endocrine treatments. Aromatase (CYP19A1) is a monooxygenase from the cytochrome P450 family that is involved in the conversion of androgens to estrogens. Breast cancer cells express aromatase activity, indicating that the tumor cells may be able to produce local estrogen. By inhibiting aromatase, serum estrogen levels decrease, which, in turn, hinders estrogen-driven cancer cell growth in hormone receptor-positive breast cancer cases. In this sense, the introduction of novel aromatase inhibitors could be a significant step forward in the fight against cancer. This is especially true in hormone-dependent cancers. Many compounds have been introduced as aromatase inhibitors, classified as steroidal or nonsteroidal. However, it should be noted that these drugs have encountered resistance in numerous cases, particularly in recent years. Thus, the search for new aromatase inhibitor drugs has always been critical. Newly, there seems to be a surge of enthusiasm in the discovery and production of molecules with dual inhibitory effects, which can inhibit two or more enzymes simultaneously. This method enables a significant reduction in potential drug resistance. The design of these compounds has an opportunity to significantly boost the efficacy of anti-cancer treatments by causing synergistic effects. This article offers a review of newly developed aromatase inhibitors with potential anticancer effects.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/acamc/10.2174/0118715206359499250318063747
2025-03-26
2026-03-11

  • From This Site

    /content/journals/acamc/10.2174/0118715206359499250318063747
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. TarverT. Cancer facts & figures; American cancer society (ACS): Atlanta, GA,201266
     [Google Scholar]
  2. ArnoldM. MorganE. RumgayH. MafraA. SinghD. LaversanneM. VignatJ. GralowJ.R. CardosoF. SieslingS. SoerjomataramI. Current and future burden of breast cancer: Global statistics for 2020 and 2040.Breast202266152310.1016/j.breast.2022.08.010 36084384
     [Google Scholar]
  3. ShoombuatongW. SchaduangratN. NantasenamatC. Towards understanding aromatase inhibitory activity via QSAR modeling.EXCLI J.201817688708 30190660
     [Google Scholar]
  4. ClusanL. FerrièreF. FlouriotG. PakdelF. A basic review on estrogen receptor signaling pathways in breast cancer.Int. J. Mol. Sci.2023247683410.3390/ijms24076834 37047814
     [Google Scholar]
  5. ŁukasiewiczS. CzeczelewskiM. FormaA. BajJ. SitarzR. StanisławekA. Breast cancer—epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—an updated review.Cancers (Basel)20211317428710.3390/cancers13174287 34503097
     [Google Scholar]
  6. LumachiF. SanteufemiaD.A. BassoS.M. Current medical treatment of estrogen receptor-positive breast cancer.World J. Biol. Chem.20156323123910.4331/wjbc.v6.i3.231 26322178
     [Google Scholar]
  7. ChanH.J. PetrossianK. ChenS. Structural and functional characterization of aromatase, estrogen receptor, and their genes in endocrine-responsive and –resistant breast cancer cells.J. Steroid Biochem. Mol. Biol.2016161738310.1016/j.jsbmb.2015.07.018 26277097
     [Google Scholar]
  8. ZarghiA. ArfaeiS. Selective COX-2 inhibitors: a review of their structure-activity relationships.Iran. J. Pharm. Res.2011104655683 24250402
     [Google Scholar]
  9. DrinaM. Peptic ulcer disease and non-steroidal anti-inflammatory drugs.Aust. Prescr.2017403919310.18773/austprescr.2017.037 28798512
     [Google Scholar]
  10. SzczukoM. KoziołI. KotlęgaD. BrodowskiJ. DrozdA. The role of thromboxane in the course and treatment of ischemic stroke.Int. J. Mol. Sci.202122211164410.3390/ijms222111644 34769074
     [Google Scholar]
  11. Abu DeiabG.I. CroattM.P. Prostacyclin (PGI2) scaffolds in medicinal chemistry: current and emerging drugs.Med. Chem. Res.20223181241125110.1007/s00044‑022‑02914‑x
     [Google Scholar]
  12. SpinelloA. RitaccoI. MagistratoA. The catalytic mechanism of steroidogenic cytochromes P450 from all-atom simulations: Entwinement with membrane environment, redox partners, and post-transcriptional regulation.Catalysts2019918110.3390/catal9010081
     [Google Scholar]
  13. ZucchiniG. GeunaE. MilaniA. AversaC. MartinelloR. MontemurroF. Clinical utility of exemestane in the treatment of breast cancer.Int. J. Womens Health20157551563 26064072
     [Google Scholar]
  14. RashdanH.R. ShehadiI.A. Triazoles synthesis & applications as nonsteroidal aromatase inhibitors for hormone-dependent breast cancer treatment.Heteroa. Chem.2022202211610.1155/2022/5349279
     [Google Scholar]
  15. KadakiaK.C. HenryN.L. Adjuvant endocrine therapy in premenopausal women with breast cancer.Clin. Adv. Hematol. Oncol.20151310663
     [Google Scholar]
  16. FabianC.J. The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer.Int. J. Clin. Pract.200761122051206310.1111/j.1742‑1241.2007.01587.x 17892469
     [Google Scholar]
  17. BrodieA. Aromatase inhibitors in breast cancer.Trends Endocrinol. Metab.2002132616510.1016/S1043‑2760(01)00529‑X 11854020
     [Google Scholar]
  18. RhoJ.M. WhiteH.S. Brief history of anti‐seizure drug development.Epilepsia Open20183S2Suppl. 211411910.1002/epi4.12268 30564769
     [Google Scholar]
  19. CocconiG. First generation aromatase inhibitors? aminoglutethimide and testololactone.Breast Cancer Res. Treat.1994301578010.1007/BF00682741 7949205
     [Google Scholar]
  20. MichaudL.B. BuzdarA.U. Risks and benefits of aromatase inhibitors in postmenopausal breast cancer.Drug Saf.199921429730910.2165/00002018‑199921040‑00005 10514021
     [Google Scholar]
  21. RaniS. RahejaK. LuxamiV. PaulK. A review on diverse heterocyclic compounds as the privileged scaffolds in non-steroidal aromatase inhibitors.Bioorg. Chem.202111310501710.1016/j.bioorg.2021.105017 34091288
     [Google Scholar]
  22. HamiltonA. PiccartM. The third-generation non-steroidal aromatase inhibitors: A review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer.Ann. Oncol.199910437738410.1023/A:1008368300827 10370778
     [Google Scholar]
  23. CuiJ. ShenY. LiR. Estrogen synthesis and signaling pathways during aging: from periphery to brain.Trends Mol. Med.201319319720910.1016/j.molmed.2012.12.007 23348042
     [Google Scholar]
  24. FuentesN. SilveyraP. Estrogen receptor signaling mechanisms.Adv. Protein Chem. Struct. Biol.201911613517010.1016/bs.apcsb.2019.01.001 31036290
     [Google Scholar]
  25. ThomasM.P. PotterB.V.L. The structural biology of oestrogen metabolism.J. Steroid Biochem. Mol. Biol.2013137274910.1016/j.jsbmb.2012.12.014 23291110
     [Google Scholar]
  26. MeyersK. LópezM. HoJ. WillsS. RayalamS. TavalS. Lipocalin-2 deficiency may predispose to the progression of spontaneous age-related adiposity in mice.Sci. Rep.20201011458910.1038/s41598‑020‑71249‑7 32883997
     [Google Scholar]
  27. ZhaoH. ZhouL. ShangguanA.J. BulunS.E. Aromatase expression and regulation in breast and endometrial cancer.J. Mol. Endocrinol.2016571R19R3310.1530/JME‑15‑0310 27067638
     [Google Scholar]
  28. BacchiS. PalumboP. SpontaA. CoppolinoM.F. Clinical pharmacology of non-steroidal anti-inflammatory drugs: a review. Anti-Inflammat. Anti-Alle.Agen. Medi. Chem.20121115264
     [Google Scholar]
  29. SostresC. GargalloC.J. ArroyoM.T. LanasA. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract.Best Pract. Res. Clin. Gastroenterol.201024212113210.1016/j.bpg.2009.11.005 20227026
     [Google Scholar]
  30. RicciottiE. FitzGeraldG.A. Prostaglandins and Inflammation.Arterioscler. Thromb. Vasc. Biol.2011315986100010.1161/ATVBAHA.110.207449 21508345
     [Google Scholar]
  31. HertelendyF. ZakárT. Prostaglandins and the myometrium and cervix.Prostaglandins Leukot. Essent. Fatty Acids200470220722210.1016/j.plefa.2003.04.009 14683694
     [Google Scholar]
  32. PingaewR. PrachayasittikulV. MandiP. NantasenamatC. PrachayasittikulS. RuchirawatS. PrachayasittikulV. Synthesis and molecular docking of 1,2,3-triazole-based sulfonamides as aromatase inhibitors.Bioorg. Med. Chem.201523133472348010.1016/j.bmc.2015.04.036 25934226
     [Google Scholar]
  33. SongJ. WuZ. WangtrakuldeeB. ChoiS.R. ZhaZ. PloesslK. MachR.H. KungH. 4-(((4-Iodophenyl)methyl)-4 H -1,2,4-triazol-4-ylamino)-benzonitrile: A Potential Imaging Agent for Aromatase.J. Med. Chem.201659209370938010.1021/acs.jmedchem.6b00849 27690428
     [Google Scholar]
  34. SongZ. LiuY. DaiZ. LiuW. ZhaoK. ZhangT. HuY. ZhangX. DaiY. Synthesis and aromatase inhibitory evaluation of 4-N-nitrophenyl substituted amino-4H-1,2,4-triazole derivatives.Bioorg. Med. Chem.201624194723473010.1016/j.bmc.2016.08.014 27567077
     [Google Scholar]
  35. El-NaggarM. Abd El-AllA.S. El-NaemS.I.A. AbdallaM.M. RashdanH.R.M. New potent 5α-Reductase and aromatase inhibitors derived from 1, 2, 3-triazole derivative.Molecules202025367210.3390/molecules25030672 32033281
     [Google Scholar]
  36. Di MatteoM. AmmazzalorsoA. AndreoliF. CaffaI. De FilippisB. FantacuzziM. GiampietroL. MaccalliniC. NencioniA. ParentiM.D. SonciniD. Del RioA. AmorosoR. Synthesis and biological characterization of 3-(imidazol-1-ylmethyl)piperidine sulfonamides as aromatase inhibitors.Bioorg. Med. Chem. Lett.201626133192319410.1016/j.bmcl.2016.04.078 27161804
     [Google Scholar]
  37. YiX.J. El-IdreesyT.T. EldebssT.M.A. FaragA.M. AbdullaM.M. HassanS.A. MabkhotY.N. Synthesis, biological evaluation, and molecular docking studies of new pyrazol‐3‐one derivatives with aromatase inhibition activities.Chem. Biol. Drug Des.201688683284310.1111/cbdd.12812 27565954
     [Google Scholar]
  38. OmarA.M.M.E. AboulWafaO.M. El-ShoukrofyM.S. Amr M.E. Benzoxazole derivatives as new generation of anti-breast cancer agents.Bioorg. Chem.20209610359310.1016/j.bioorg.2020.103593 32004897
     [Google Scholar]
  39. StefanachiA. HankeN. PisaniL. LeonettiF. NicolottiO. CattoM. CellamareS. HartmannR.W. CarottiA. Discovery of new 7-substituted-4-imidazolylmethyl coumarins and 4′-substituted-2-imidazolyl acetophenones open analogues as potent and selective inhibitors of steroid-11β-hydroxylase.Eur. J. Med. Chem.20158910611410.1016/j.ejmech.2014.10.021 25462231
     [Google Scholar]
  40. LokeshB.V. PrasadY.R. ShaikA.B. Synthesis, Biological evaluation and molecular docking studies of new pyrazolines as an antitubercular and cytotoxic agents. Infect. Disord.-.Drug Targ.2019193310321
     [Google Scholar]
  41. ChamduangC. PingaewR. PrachayasittikulV. PrachayasittikulS. RuchirawatS. PrachayasittikulV. Novel triazole-tetrahydroisoquinoline hybrids as human aromatase inhibitors.Bioorg. Chem.20199310332710.1016/j.bioorg.2019.103327 31614285
     [Google Scholar]
  42. PragathiY.J. SreenivasuluR. VeronicaD. RajuR.R. Design, synthesis, and biological evaluation of 1, 2, 4-thiadiazole-1, 2, 4-triazole derivatives bearing amide functionality as anticancer agents.Arab. J. Sci. Eng.202146122523210.1007/s13369‑020‑04626‑z 32837812
     [Google Scholar]
  43. KangH. XiaoX. HuangC. YuanY. TangD. DaiX. ZengX. Potent aromatase inhibitors and molecular mechanism of inhibitory action.Eur. J. Med. Chem.201814342643710.1016/j.ejmech.2017.11.057 29202405
     [Google Scholar]
  44. AmmazzalorsoA. GalloriniM. FantacuzziM. GambacortaN. De FilippisB. GiampietroL. MaccalliniC. NicolottiO. CataldiA. AmorosoR. Design, synthesis and biological evaluation of imidazole and triazole-based carbamates as novel aromatase inhibitors.Eur. J. Med. Chem.202121111311510.1016/j.ejmech.2020.113115 33360796
     [Google Scholar]
  45. SağlıkB.N. ŞenA.M. EvrenA.E. ÇevikU.A. OsmaniyeD. Kaya ÇavuşoğluB. LeventS. KaradumanA.B. ÖzkayY. KaplancıklıZ.A. Synthesis, investigation of biological effects and in silico studies of new benzimidazole derivatives as aromatase inhibitors.Z. Naturforsch. C J. Biosci.2020759-1035336210.1515/znc‑2020‑0104 32681791
     [Google Scholar]
  46. DoironJ. SoultanA.H. RichardR. TouréM.M. PicotN. RichardR. Čuperlović-CulfM. RobichaudG.A. TouaibiaM. Synthesis and structure–activity relationship of 1- and 2-substituted-1,2,3-triazole letrozole-based analogues as aromatase inhibitors.Eur. J. Med. Chem.20114694010402410.1016/j.ejmech.2011.05.074 21703734
     [Google Scholar]
  47. PratapR. RamV.J. Natural and synthetic chromenes, fused chromenes, and versatility of dihydrobenzo[h]chromenes in organic synthesis.Chem. Rev.201411420104761052610.1021/cr500075s 25303539
     [Google Scholar]
  48. PatilS.A. PatilS.A. PatilR. Microwave-assisted synthesis of chromenes: biological and chemical importance.Future Med. Chem.20157789390910.4155/fmc.15.38 26061107
     [Google Scholar]
  49. MajumdarN. PaulN.D. MandalS. de BruinB. WulffW.D. Catalytic synthesis of 2 H-chromenes.ACS Catal.2015542329236610.1021/acscatal.5b00026
     [Google Scholar]
  50. BhuvaneswariK. SivaguruP. LalithaA. Synthesis, anticancer evaluation, and docking studies of some novel azo chromene derivatives.J. Chin. Chem. Soc. (Taipei)202067101877188610.1002/jccs.201900481
     [Google Scholar]
  51. GhorabM.M. AlsaidM.S. Al-AnsaryG.H. Abdel-LatifG.A. Abou El EllaD.A. Analogue based drug design, synthesis, molecular docking and anticancer evaluation of novel chromene sulfonamide hybrids as aromatase inhibitors and apoptosis enhancers.Eur. J. Med. Chem.201612494695810.1016/j.ejmech.2016.10.020 27770735
     [Google Scholar]
  52. GobbiS. HuQ. ZimmerC. EngelM. BellutiF. RampaA. HartmannR.W. BisiA. Exploiting the chromone scaffold for the development of inhibitors of corticosteroid biosynthesis.J. Med. Chem.20165962468247710.1021/acs.jmedchem.5b01609 26938274
     [Google Scholar]
  53. fürstner, A.; Jumbam, D.N.; Seidel, G. Syntheses of Zindoxifene and Analogues by Titanium‐Induced Oxo‐Amide Coupling.Chem. Ber.199412761125113010.1002/cber.19941270624
     [Google Scholar]
  54. PriorA.M. YuX. ParkE.J. KondratyukT.P. LinY. PezzutoJ.M. SunD. Structure-activity relationships and docking studies of synthetic 2-arylindole derivatives determined with aromatase and quinone reductase 1.Bioorg. Med. Chem. Lett.201727245393539910.1016/j.bmcl.2017.11.010 29153737
     [Google Scholar]
  55. PingaewR. MandiP. PrachayasittikulV. PrachayasittikulS. RuchirawatS. PrachayasittikulV. Synthesis, molecular docking, and QSAR study of sulfonamide-based indoles as aromatase inhibitors.Eur. J. Med. Chem.20181431604161510.1016/j.ejmech.2017.10.057 29137864
     [Google Scholar]
  56. FantacuzziM. De FilippisB. GalloriniM. AmmazzalorsoA. GiampietroL. MaccalliniC. AturkiZ. DonatiE. IbrahimR.S. ShawkyE. CataldiA. AmorosoR. Synthesis, biological evaluation, and docking study of indole aryl sulfonamides as aromatase inhibitors.Eur. J. Med. Chem.202018511181510.1016/j.ejmech.2019.111815 31732252
     [Google Scholar]
  57. MarellaA. Rahmat AliM. AlamT.M. SahaR. TanwarO. AkhterM. ShaquiquzzamanM. Mumtaz AlamM. Pyrazolines: a biological review.Mini Rev. Med. Chem.201313692193110.2174/1389557511313060012 23544604
     [Google Scholar]
  58. BergstromF.W. Heterocyclic nitrogen compounds. Part IIA. hexacyclic compounds: Pyridine, quinoline, and isoquinoline.Chem. Rev.19443527727710.1021/cr60111a001
     [Google Scholar]
  59. GrombeinC.M. HuQ. RauS. ZimmerC. HartmannR.W. Heteroatom insertion into 3,4-dihydro-1H-quinolin-2-ones leads to potent and selective inhibitors of human and rat aldosterone synthase.Eur. J. Med. Chem.20159078879610.1016/j.ejmech.2014.12.022 25528333
     [Google Scholar]
  60. BurdzhievN.T. BaramovT.I. StanoevaE.R. YanevS.G. StoyanovaT.D. DimitrovaD.H. KostadinovaK.A. Synthesis of novel trans-4-(phthalimidomethyl)- and 4-(imidazol-1-ylmethyl)-3-indolyl-tetrahydroisoquinolinones as possible aromatase inhibitors.Chem. Pap.20197351263127710.1007/s11696‑018‑00677‑7
     [Google Scholar]
  61. GhodsiR. AziziE. FerlinG.M. PezziV. ZarghiA. Design, synthesis and biological evaluation of 4-(imidazolylmethyl)-2-aryl-quinoline derivatives as aromatase inhibitors and anti-breast cancer agents.Lett. Drug Des. Discov.2015131899710.2174/1570180812666150611185605
     [Google Scholar]
  62. MovassaghiM. HillM.D. AhmadO.K. Direct synthesis of pyridine derivatives.J. Am. Chem. Soc.200712933100961009710.1021/ja073912a 17663557
     [Google Scholar]
  63. PatelK.S. RavalK.N. PatelS.P. PatelA.G. PatelS.V. A review on synthesis and biological activities of pyrimidine derivatives.Int. J. Pharm. Bio. Sci.201223170182
     [Google Scholar]
  64. KuruvaC.S. GandavaramS.P. KadiamV.S. ValluruL. ChamarthiN.R. Synthesis of new heteroaryl α‐aminophosphonates and evaluation of their cytotoxicity against human breast cancer MCF‐7 cell lines.ChemistrySelect20183236479648710.1002/slct.201800700
     [Google Scholar]
  65. HuQ. KundeJ. HankeN. HartmannR.W. Identification of 4-(4-nitro-2-phenethoxyphenyl)pyridine as a promising new lead for discovering inhibitors of both human and rat 11β-Hydroxylase.Eur. J. Med. Chem.20159613915010.1016/j.ejmech.2015.04.013 25874338
     [Google Scholar]
  66. ErtasM. SahinZ. BerkB. YurttasL. BiltekinS.N. DemirayakS. Pyridine‐substituted thiazolylphenol derivatives: Synthesis, modeling studies, aromatase inhibition, and antiproliferative activity evaluation.Arch. Pharm. (Weinheim)20183513-4170027210.1002/ardp.201700272 29522642
     [Google Scholar]
  67. AboulWafaO.M. DaabeesH.M.G. BadawiW.A. 2-Anilinopyrimidine derivatives: Design, synthesis, in vitro anti-proliferative activity, EGFR and ARO inhibitory activity, cell cycle analysis and molecular docking study.Bioorg. Chem.20209910379810.1016/j.bioorg.2020.103798 32247112
     [Google Scholar]
  68. GomhaS.M. AbdelrazekF.M. AbdullaM.M. Synthesis of new functionalised derivatives of [1, 2, 4] triazolo [4, 3-a] pyrimidine and pyrimido [2, 1-b][1, 3, 5] thiadiazine as aromatase inhibitors.J. Chem. Res.201539742542910.3184/174751915X14360216187281
     [Google Scholar]
  69. SahinZ. ErtasM. BerkB. BiltekinS.N. YurttasL. DemirayakS. Studies on non-steroidal inhibitors of aromatase enzyme; 4-(aryl/heteroaryl)-2-(pyrimidin-2-yl)thiazole derivatives.Bioorg. Med. Chem.20182681986199510.1016/j.bmc.2018.02.048 29525337
     [Google Scholar]
  70. LicznerskaB. SzaeferH. WierzchowskiM. MikstackaR. PapierskaK. Baer-DubowskaW. Evaluation of the effect of the new methoxy-stilbenes on expression of receptors and enzymes involved in estrogen synthesis in cancer breast cells.Mol. Cell. Biochem.20184441-2536210.1007/s11010‑017‑3230‑7 29189985
     [Google Scholar]
  71. NielsenA.J. Raez-VillanuevaS. CrankshawD.J. HollowayA.C. McNultyJ. Synthesis of α-methylstilbenes using an aqueous Wittig methodology and application toward the development of potent human aromatase inhibitors.Bioorg. Med. Chem. Lett.201929111395139810.1016/j.bmcl.2019.03.033 30952594
     [Google Scholar]
  72. OrsiniF. VerottaL. KlimoK. GerhäuserC. Synthesis of resveratrol derivatives and in vitro screening for potential cancer chemopreventive activities.Arch. Pharm. (Weinheim)2016349641442710.1002/ardp.201600022 27159630
     [Google Scholar]
  73. BlassB.E. IyerP. Abou-GharbiaM. ChildersW.E. GordonJ.C. RamanjuluM. MortonG. ArumugamP. BoruwaJ. EllingboeJ. MitraS. NimmareddyR.R. PaliwalS. RajasekharJ. ShivakumarS. SrivastavaP. TangiralaR.S. VenkataramanaiahK. BobbalaR. YanamandraM. Krishnakanth ReddyL. Design and synthesis of functionalized piperazin-1yl-(E)-stilbenes as inhibitors of 17α-hydroxylase-C17,20-lyase (Cyp17).Bioorg. Med. Chem. Lett.201828132270227410.1016/j.bmcl.2018.05.040 29803730
     [Google Scholar]
  74. KhanF.A. MushtaqS. NazS. FarooqU. ZaidiA. BukhariS.M. RaufA. MubarakM.S. Sulfonamides as potential bioactive scaffolds.Curr. Org. Chem.201822881883010.2174/1385272822666180122153839
     [Google Scholar]
  75. LeechaisitR. PingaewR. PrachayasittikulV. WorachartcheewanA. PrachayasittikulS. RuchirawatS. PrachayasittikulV. Synthesis, molecular docking, and QSAR study of bis-sulfonamide derivatives as potential aromatase inhibitors.Bioorg. Med. Chem.2019271911504010.1016/j.bmc.2019.08.001 31416738
     [Google Scholar]
  76. LuW.J. XuC. PeiZ. MayhoubA.S. CushmanM. FlockhartD.A. The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents.Breast Cancer Res. Treat.201213319910910.1007/s10549‑011‑1699‑4 21814747
     [Google Scholar]
  77. ZhaoL.M. JinH.S. LiuJ. SkaarT.C. IpeJ. LvW. FlockhartD.A. CushmanM. A new Suzuki synthesis of triphenylethylenes that inhibit aromatase and bind to estrogen receptors α and β.Bioorg. Med. Chem.201624215400540910.1016/j.bmc.2016.08.064 27647367
     [Google Scholar]
  78. LvW. LiuJ. SkaarT.C. O’NeillE. YuG. FlockhartD.A. CushmanM. Synthesis of triphenylethylene bisphenols as aromatase inhibitors that also modulate estrogen receptors.J. Med. Chem.201659115717010.1021/acs.jmedchem.5b01677 26704594
     [Google Scholar]
  79. CooganM.P. DysonP.J. BochmannM. Introduction to the organometallics in biology and medicine issue.Organometallics201231165671567210.1021/om300737y
     [Google Scholar]
  80. MudiS. UsmanM. IbrahimS. Clinical and industrial application of organometallic compounds and complexes: a review.Am. J. Chem. Appl201526151158
     [Google Scholar]
  81. HussainR.A. BadshahA. PezzutoJ.M. AhmedN. KondratyukT.P. ParkE.J. Ferrocene incorporated selenoureas as anticancer agents.J. Photochem. Photobiol. B201514819720810.1016/j.jphotobiol.2015.04.024 25966308
     [Google Scholar]
  82. GolbaghiG. HaghdoostM.M. YancuD. López de los SantosY. DoucetN. PattenS.A. SandersonJ.T. CastonguayA. Organoruthenium (II) complexes bearing an aromatase inhibitor: synthesis, characterization, in vitro biological activity and in vivo toxicity in zebrafish embryos.Organometallics201938370271110.1021/acs.organomet.8b00897 31762529
     [Google Scholar]
  83. GolbaghiG. PitardI. LucasM. HaghdoostM.M. de los SantosY.L. DoucetN. PattenS.A. SandersonJ.T. CastonguayA. Synthesis and biological assessment of a ruthenium(II) cyclopentadienyl complex in breast cancer cells and on the development of zebrafish embryos.Eur. J. Med. Chem.202018811203010.1016/j.ejmech.2019.112030 31945643
     [Google Scholar]
  84. CaciollaJ. SpinelloA. MartiniS. BisiA. ZaffaroniN. GobbiS. MagistratoA. Targeting orthosteric and allosteric pockets of aromatase via dual-mode novel azole inhibitors.ACS Med. Chem. Lett.202011573273910.1021/acsmedchemlett.9b00591 32435378
     [Google Scholar]
  85. GobbiS. ZimmerC. BellutiF. RampaA. HartmannR.W. RecanatiniM. BisiA. Novel highly potent and selective nonsteroidal aromatase inhibitors: synthesis, biological evaluation and structure-activity relationships investigation.J. Med. Chem.201053145347535110.1021/jm100319h 20568782
     [Google Scholar]
  86. GobbiS. CavalliA. NegriM. ScheweK.E. BellutiF. PiazziL. HartmannR.W. RecanatiniM. BisiA. Imidazolylmethylbenzophenones as highly potent aromatase inhibitors.J. Med. Chem.200750153420342210.1021/jm0702938 17585752
     [Google Scholar]
  87. GobbiS. HuQ. FoschiG. CatanzaroE. BellutiF. RampaA. FimognariC. HartmannR.W. BisiA. Benzophenones as xanthone-open model CYP11B1 inhibitors potentially useful for promoting wound healing.Bioorg. Chem.20198640140910.1016/j.bioorg.2019.01.066 30769265
     [Google Scholar]
  88. ZhangM. ParkE.J. KondratyukT.P. PezzutoJ.M. SunD. Synthesis and structure–activity relationships of tetrahydro-β-carboline derivatives as anticancer and cancer-chemopreventive agents.Anticancer Res.20183884425443310.21873/anticanres.12744 30061206
     [Google Scholar]
  89. Acar ÇevikU. SağlıkB.N. OsmaniyeD. LeventS. Kaya ÇavuşoğluB. KaradumanA.B. ÖzkayY. KaplancıklıZ.A. Synthesis and docking study of benzimidazole–triazolothiadiazine hybrids as aromatase inhibitors.Arch. Pharm. (Weinheim)20203535e200000810.1002/ardp.202000008 32159244
     [Google Scholar]
  90. SableP.M. PoteyL.C. Synthesis and antiproliferative activity of imidazole and triazole derivatives of flavonoids.Pharm. Chem. J.201852543844310.1007/s11094‑018‑1836‑z
     [Google Scholar]
  91. VarelaC.L. AmaralC. Correia-da-SilvaG. CostaS.C. CarvalhoR.A. CostaG. AlcaroS. TeixeiraN.A.A. Tavares-da-SilvaE.J. RoleiraF.M.F. Exploring new chemical functionalities to improve aromatase inhibition of steroids.Bioorg. Med. Chem.201624122823283110.1016/j.bmc.2016.04.056 27160054
     [Google Scholar]
  92. HoweL.R. DannenbergA.J. COX-2 inhibitors for the prevention of breast cancer.J. Mammary Gland Biol. Neoplasia200381314310.1023/A:1025731204719 14587862
     [Google Scholar]
  93. HarrisR.E. Cyclooxygenase-2 (cox-2) and the inflammogenesis of cancer.Subcell. Biochem.2007429312610.1007/1‑4020‑5688‑5_4 17612047
     [Google Scholar]
  94. FalandryC. CanneyP.A. FreyerG. DirixL.Y. Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer.Ann. Oncol.200920461562010.1093/annonc/mdn693 19254941
     [Google Scholar]
  95. BundredN.J. BarnesN.L.P. Potential use of COX-2–aromatase inhibitor combinations in breast cancer.Br. J. Cancer200593S1S10S1510.1038/sj.bjc.6602690 16100520
     [Google Scholar]
  96. DuttaU. PantK. Aromatase inhibitors: past, present and future in breast cancer therapy.Med. Oncol.200825211312410.1007/s12032‑007‑9019‑x 17973095
     [Google Scholar]
  97. HongY. ChenS. Aromatase Inhibitors.Ann. N. Y. Acad. Sci.20061089123725110.1196/annals.1386.022 17261771
     [Google Scholar]
  98. SuB. CaiX. HongY. ChenS. COX-2 inhibitor nimesulide analogs are aromatase suppressors in breast cancer cells.J. Steroid Biochem. Mol. Biol.2010122423223810.1016/j.jsbmb.2010.06.004 20542113
     [Google Scholar]
  99. ChumsriS. HowesT. BaoT. SabnisG. BrodieA. Aromatase, aromatase inhibitors, and breast cancer.J. Steroid Biochem. Mol. Biol.20111251-2132210.1016/j.jsbmb.2011.02.001 21335088
     [Google Scholar]
  100. A A FadalyW. A M M ElshaierY. T M NemrM. R A AbdellatifK. Design, synthesis, modeling studies and biological evaluation of pyrazole derivatives linked to oxime and nitrate moieties as nitric oxide donor selective COX-2 and aromatase inhibitors with dual anti-inflammatory and anti-neoplastic activities.Bioorg. Chem.202313410642810.1016/j.bioorg.2023.106428 36893546
     [Google Scholar]
/content/journals/acamc/10.2174/0118715206359499250318063747
Loading
Recent Advances in Therapeutic Potential of Dual-Acting Aromatase/COX-2
Anti-Cancer Agents in Medicinal Chemistry 26, 26 (2026); https://doi.org/10.2174/0118715206359499250318063747
/content/journals/acamc/10.2174/0118715206359499250318063747
/content/journals/acamc/10.2174/0118715206359499250318063747
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): anticancer; aromatase; aromatase inhibitors; aromatase/COX-2; COX-2; Dual-acting

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test